Yingrui Dai

Title: Innovations of Yingrui Dai in JAK1 Inhibitors

Introduction

Yingrui Dai is a notable inventor based in Wilmington, DE (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of JAK1 inhibitors. With a total of 2 patents to his name, his work is recognized for its potential impact on therapeutic applications.

Latest Patents

Yingrui Dai's latest patents include innovative processes for preparing a JAK1 inhibitor. One of his patents details the preparation of 4-[3-(cyanomethyl)-3-(3',5′-dimethyl-1H, 1′H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide, along with its phosphoric acid salt. This compound is recognized for its selectivity as a Janus kinase 1 (JAK1) inhibitor. Additionally, he has developed processes for preparing new forms of this JAK1 inhibitor, further expanding the potential applications of his research.

Career Highlights

Yingrui Dai is currently associated with Incyte Corporation, where he continues to advance his research in the pharmaceutical industry. His work has been instrumental in the development of targeted therapies, showcasing his expertise in medicinal chemistry and drug development.

Collaborations

Yingrui has collaborated with notable colleagues, including Jiacheng Zhou and Zhongjiang Jia, who contribute to his innovative projects. Their combined efforts enhance the research and development processes within their field.

Conclusion

Yingrui Dai's contributions to the development of JAK1 inhibitors highlight his role as a significant inventor in the pharmaceutical industry. His innovative processes and collaborations continue to pave the way for advancements in targeted therapies.